Nivolumab plus chemotherapy improves survival in Stage III Non-Small-Cell Lung Cancer: NEJM
Spain: A recent study published in The New England Journal of Medicine has revealed that combining Nivolumab and Chemotherapy treatment in patients with Stage III Non–Small-Cell Lung Cancer improves pathological response outcomes and higher survival rates.
The use of perioperative nivolumab in combination with chemotherapy for patients with resectable stage IIIA or IIIB NSCLC suggested that incorporating neoadjuvant nivolumab into the treatment regimen could be a metamorphic for stage III NSCLC patients, ultimately enhancing their overall outcomes and quality of life.
A population constituting around 20% of all NSCLC cases receive a diagnosis of stage III disease. Lack of consensus prompted Dr Mariano et al. to conduct an open-label phase 2 trial investigating the benefits of perioperative treatment with nivolumab, an immune checkpoint inhibitor, combined with chemotherapy.
In this trial, the patients with resectable stage IIIA or IIIB NSCLC were randomly assigned to one of two groups: an experimental group receiving neoadjuvant nivolumab plus platinum-based chemotherapy, or a control group receiving chemotherapy alone, followed by surgery. The experimental group with R0 resections subsequently received adjuvant treatment with nivolumab for six months.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.